| Primary | Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population. | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | AUC(0-inf) of GSK2982772 in MT Formulation :Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| |
| Primary | AUC(0-t) of GSK2982772 in MT Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t) | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A:MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| |
| Primary | AUC(0-24) of GSK2982772 in MT Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24) | PK Population. Only those participants with data available at specified time frame were analyzed | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A:MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| |
| Primary | AUC(0-12) of GSK2982772 in MT Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12) | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A:MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A:MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for Cmax | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| | |
| Primary | Cmax of GSK2982772 in MT Formulation: Part A | Blood samples were collected from participants at indicated time points and analyzed for Cmax | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A | Blood samples were collected from participants at indicated time points and analyzed for C12hour. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal | | OG003 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
|
| Primary | Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A | Blood samples were collected from participants at indicated time points and analyzed for C24hour. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal | | OG003 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
|
| Primary | Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A | Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test) | | | | ID | Title | Description |
|---|
| OG000 | Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses | | OG001 | Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses |
| |
| Primary | Frelformulation Based on AUC (0-24) of GSK2982772 in Part A | Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test) | | | | ID | Title | Description |
|---|
| OG000 | Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses | | OG001 | Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses |
| |
| Primary | Frelformulation Based on Cmax of GSK2982772 in Part A | Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test) | | | | ID | Title | Description |
|---|
| OG000 | Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses | | OG001 | Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses |
| |
| Primary | Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| |
| Primary | Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| |
| Primary | Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A | Blood samples were collected at indicated time points for analysis of Tmax. | | Posted | | Median | Full Range | Hours | | Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
| | |
| Primary | Tmax of GSK2982772 in MT Formulation: Part A | Blood samples were collected at indicated time points for analysis of Tmax. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Median | Full Range | Hours | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
| |
| Primary | AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-inf) | PK Population. Only those participants with data available at specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| |
| Primary | AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-inf). | PK Population. Only those participants with data available at specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-t). | PK Population. Only those participants with data available at specified time frame were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| |
| Primary | AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-t). | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-24) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| | |
| Primary | AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-24) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-12) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| | |
| Primary | AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of AUC (0-12) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | Cmax of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of Cmax | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| | |
| Primary | Cmax of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of Cmax | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | C12 of GSK2982772 in Part C: Fasted State | Blood samples was collected at indicated time point for analysis of C12 | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG002 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | C24 of GSK2982772 in Part C: Fasted State | Blood samples was collected at indicated time point for analysis of C24 | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram per milliliter | | 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG002 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| |
| Primary | Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state |
| |
| Primary | Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented. | | Posted | | Mean | Standard Deviation | Ratio | | Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C: MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state | | OG001 | Part C: MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
| |
| Primary | Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100. | | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test) | | | | ID | Title | Description |
|---|
| OG000 | Part C:MM-12h 240mg Fasted and IR 240mg Fasted | Participants in received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state and a single dose of 240 mg GSK2982772 IR tablet in fasted state. There was washout period of 7 days between doses |
| |
| Primary | Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State | Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at the specified data points were analyzed | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test) | | | | ID | Title | Description |
|---|
| OG000 | Part C:MM-12h 240mg Fasted and IR 240mg Fasted | Participants in received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state and a single dose of 240 mg GSK2982772 IR tablet in fasted state. There was washout period of 7 days between doses |
| |
| Secondary | Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A | Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at the specified time points were analyzed. | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A:120 mg MT-12hour Fed and 120 mg MT-12hour Fasted | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal and received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses |
| |
| Secondary | Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A | Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100. | PK Population. Only those participants with data available at specified timepoint were analyzed | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part A:120 mg MT-12hour Fed and 120 mg MT-12hour Fasted | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal and received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses |
| |
| Secondary | AUC(0-24) of GSK2982772 in Part B | Blood samples were collected at indicated time points for analysis of AUC (0-24) | PK Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram/milliliter | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Cmax of GSK2982772 in Part B | Blood samples were collected at indicated time points for analysis of Cmax | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram/milliliter | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Tmax of GSK2982772 in Part B | Blood samples were collected at indicated time points for analysis of Tmax | | Posted | | Median | Full Range | Hours | | Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | AUC (0-24) of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of AUC (0-24) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram/milliliter | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | Cmax of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of Cmax | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram/milliliter | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | C12 of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of C12 | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Microgram/milliliter | | 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | AUC(0-t) of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of AUC (0-t) | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram/milliliter | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | AUC(0-inf) of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal. | PK Population. Only participants with data available at the specified time points were analyzed. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram/milliliter | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | AUC(0-12) of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal. | | Posted | | Geometric Mean | Geometric Coefficient of Variation | Hours*microgram/milliliter | | Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100. | | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C:480mg MM-12hour Delayed Fed and 480 mg MM-12hour Fasted | Participants received single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses | | OG001 | Part C:480mg MM-12hour Fed and 480 mg MM- 12hour Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses | | OG002 | Part C:240mg MM-12hour Delayed Fed and 240mg MM-12hour Fasted |
|
| Secondary | Frelformulation Based on Cmax of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100. | | Posted | | Number | 90% Confidence Interval | Percentage bioavailability | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C:480mg MM-12hour Delayed Fed and 480 mg MM-12hour Fasted | Participants received single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses | | OG001 | Part C:480mg MM-12hour Fed and 480 mg MM- 12hour Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses | | OG002 | Part C:240mg MM-12hour Delayed Fed and 240mg MM-12hour Fasted |
|
| Secondary | Tmax of GSK2982772 After Meal in Part C | Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal. | | Posted | | Median | Full Range | Hours | | Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose | | | | ID | Title | Description |
|---|
| OG000 | Part C MM-12h 480mg Delayed Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed). | | OG001 | Part C MM-12h 240mg Delayed Fed (High Fat) | Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed). | | OG002 | Part C MM-12h 480mg Fed (Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
| |
| Secondary | Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A | An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state | | OG001 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG002 | Part A: MT-8hour 120mg Fasted |
|
| Secondary | Number of Participants With AE and SAE in Part B | An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. | | Posted | | Count of Participants | | Participants | | Up to Day 22 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
|
| Secondary | Number of Participants With AE and SAE in Part C | An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state |
|
| Secondary | Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A | Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state |
|
| Secondary | Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A | Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 |
|
| Secondary | Number of Participants Abnormal Urinalysis Dipstick Results: Part A | Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal | | OG003 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state |
|
| Secondary | Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B | Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 22 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | |
|
| Secondary | Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B | Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 22 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 |
|
| Secondary | Number of Participants Abnormal Urinalysis Dipstick Results: Part B | Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal. | | Posted | | Count of Participants | | Participants | | Up to Day 22 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C | Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 |
|
| Secondary | Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C | Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted |
|
| Secondary | Number of Participants Abnormal Urinalysis Dipstick Results: Part C | Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
|
| Secondary | Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A | Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state | | OG001 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG002 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal | | OG003 |
|
| Secondary | Number of Participants Abnormal ECG Findings: Part B | Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 22 | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Number of Participants Abnormal ECG Findings: Part C | Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported. | | Posted | | Count of Participants | | Participants | | Up to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | |
|
| Secondary | Change From Baseline in Blood Pressure: Part A | Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Posted | | Mean | Standard Deviation | Millimeters of mercury | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state | | OG001 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. | | OG002 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG003 |
|
| Secondary | Change From Baseline in Heart Rate: Part A | Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Beats per minute | | Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state | | OG001 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. | | OG002 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG003 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
|
| Secondary | Change From Baseline in Respiration Rate: Part A | Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value | | Posted | | Mean | Standard Deviation | Breaths per minute | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state | | OG001 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. | | OG002 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG003 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
|
| Secondary | Change From Baseline in Body Temperature: Part A | Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Degree Celsius | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part A: IR 120mg Fasted | Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state | | OG001 | Part A: MT-12hour 120mg Fasted | Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. | | OG002 | Part A: MT-8hour 120mg Fasted | Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state | | OG003 | Part A: MT-12hour 120mg Fed (High Fat) | Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal |
|
| Secondary | Change From Baseline in Blood Pressure: Part B | SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Millimeters of mercury | | Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Change From Baseline in Heart Rate: Part B | Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Beats per minute | | Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Change From Baseline in Respiration Rate: Part B | Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value | | Posted | | Mean | Standard Deviation | Breaths per minute | | Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Change From Baseline in Body Temperature: Part B | Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Degree Celsius | | Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours | | | | ID | Title | Description |
|---|
| OG000 | Part B: MT-12 120mg Fasted | Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days. | | OG001 | Part B :MT-12 240mg Fasted | Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days | | OG002 | Part B :MT-12hour 300mg Fed (Standard) | Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days |
| |
| Secondary | Change From Baseline in Blood Pressure: Part C | SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Millimeters of mercury | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
|
| Secondary | Change From Baseline in Heart Rate: Part C | Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Beats per minute | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
|
| Secondary | Change From Baseline in Respiration Rate: Part C | Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Breaths per minute | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
|
| Secondary | Change From Baseline in Body Temperature: Part C | Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value. | | Posted | | Mean | Standard Deviation | Degree Celsius | | Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours | | | | ID | Title | Description |
|---|
| OG000 | Part C: IR 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state | | OG001 | Part C:MM-12h 240mg Fasted | Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state. | | OG002 | Part C:MM-12h 480mg Fasted | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state | | OG003 | Part C:MM-12h 480mg Fed(Standard) | Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state |
|